Personalis Announces Illumina CSPro Certification for Sequencing

  Personalis Announces Illumina CSPro Certification for Sequencing

Business Wire

MENLO PARK, Calif. -- May 7, 2013

Personalis announced today that it has successfully completed Illumina CSPro™
certification for sequencing on HiSeq and MiSeq, gaining entry to an elite
group of Illumina genomics service providers globally. Illumina Inc., a San
Diego-based company, provides leading-edge genetic analysis tools to genomics
centers worldwide.

Illumina CSPro is the collaborative service provider partnership dedicated to
ensuring the delivery of the highest-quality data available for genetic
analysis applications. Illumina CSPro participants undergo a rigorous
two-phase certification process that includes minimum data generation, data
certification, and an on-site audit of the facility and processes.

John West, Personalis’s CEO said, "Our state of the art laboratory is
committed to excellence at each step of the process and our deep knowledge of
the Illumina technology platform allows us to provide an end to end service
that meets the needs of researchers in academia, pharma and clinicians as
well. We value Illumina’s commitment to maintain that level of excellence and
welcome the opportunity to be a CSPro global partner."

"Illumina CSPro recognizes organizations that provide customers with
industry-leading data quality and service in genetic analysis," said Karen
Possemato, Illumina's Sr. Director of Corporate Marketing. "Personalis is now
a Certified Service Provider in Menlo Park, California able to provide
comprehensive sequencing services using Illumina technology. Now that
Personalis is a global CSPro partner, we are excited to work with them to make
it easier for researchers and clinicians in the US and elsewhere to access the
power of Illumina's genetic analysis technologies."

About Personalis

Personalis provides researchers and clinicians accurate DNA sequencing and
interpretation of human genomes. We support researchers engaging in
case-control, family-based, or proband-only genome studies of disease,
pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced)
Technology™ can supplement a standard exome or genome, substantially
increasing its medically-relevant coverage and accuracy. Personalis builds on
this foundation with innovative algorithms and proprietary databases for
alignment, variant calling, annotation, and analysis. With this combination,
we provide genomic data and interpretation of the highest accuracy.
(www.personalis.com)

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130507005631/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50626487&lang=en

Contact:

Personalis
Carol Tillis, 1-650-752-1300
pr@personalis.com
www.personalis.com